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Isolation of T cell receptors targeting
recurrent neoantigens in hematological
malignancies
Vanessa M. Tubb1* , Deborah S. Schrikkema1, Nathan P. Croft2, Anthony W. Purcell2, Carsten Linnemann3,
Manon R. Freriks3, Frederick Chen4, Heather M. Long1, Steven P. Lee1 and Gavin M. Bendle1
Abstract
Mutation-derived neoantigens represent an important class of tumour-specific, tumour rejection antigens, and are
attractive targets for TCR gene therapy of cancer. The majority of such mutations are patient-specific and targeting
these requires a fully personalized approach. However, some mutations are found recurrently among cancer
patients, and represent potential targets for neoantigen-specific TCR gene therapy that is more widely applicable.
Therefore, we have investigated if some cancer mutations found recurrently in hematological malignancies encode
immunogenic neoantigens presented by common European Caucasoid HLA class I alleles and can form targets for
TCR gene therapy. We initially focused on identifying HLA class I neoepitopes derived from calreticulin (CALR) exon
9 mutations, found in ~ 80% of JAK2wt myeloproliferative neoplasms (MPN). Based on MHC class I peptide
predictions, a number of peptides derived from mutant CALR (mCALR) were predicted to bind to HLA-A*03:01 and
HLA-B*07:02. However, using mass spectrometry and ex vivo pMHC multimer staining of PBMC from MPN patients
with CALR exon 9 mutations, we found no evidence that these peptides were naturally processed and presented
on the surface of mCALR-expressing target cells. We next developed a protocol utilizing pMHC multimers to isolate
CD8+ T cells from healthy human donor PBMC that are specific for mCALR and additional putative neoepitopes
found recurrently in hematological malignancies. Using this approach, CD8+ T cells specific for HLA-A*03:01- and
HLA-B*07:02-presented mCALR peptides and an HLA-A*11:01-presented mutant FBXW7 (mFBXW7) peptide were
successfully isolated. TCRs isolated from mCALR-specific CD8+ T cell populations were not able to recognize target
cells engineered to express mCALR. In contrast, mFBXW7-specific CD8+ T cells were able to recognize target cells
engineered to express mFBXW7. In conclusion, while we found no evidence for mCALR derived neoepitope
presentation in the context of the HLA class I alleles studied, our data suggests that the recurrent pR465H mutation
in FBXW7 may encode an HLA-A*11:01 presented neoepitope, and warrants further investigation as a target for T
cell based immunotherapy of cancer.
Keywords: Neoantigens, TCR gene therapy, CALR, FBXW7, Immunotherapy
Background
Non-synonymous somatic mutations can encode neoanti-
gens that are processed and presented by major histocom-
patibility complexes (MHC) on the surface of mutated
tumour cells. Recognition of neoantigens by the endogen-
ous T cell repertoire has been shown to contribute to the
therapeutic efficacy of cancer immunotherapy in both
mice and humans [1–6]. Therefore, neoantigens represent
an important class of tumour-specific, tumour rejection
antigens, which can be targeted by neoantigen-specific T
cell receptors (TCRs). The majority of such mutations are
known to be unique to individual patients and targeting
these would thus require a fully personalized approach.
However, in addition to these patient-specific mutations,
some mutations are found recurrently among particular
groups of cancer patients. These shared mutations repre-
sent potential targets for a more widely applicable T
cell-based immunotherapy.
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In 2013, mutations in exon 9 of the calreticulin gene
(CALR) were discovered in ~ 80% of JAK2wt myelopro-
liferative neoplasm patients (MPN) [7, 8]. Intriguingly,
all these exon 9 mutations result in a + 1 bp frameshift
resulting in a gain of 36 amino acids. This generates a
novel C terminus of the protein that is common to all
MPN patients carrying mutations in CALR exon 9.
Importantly, CALR exon 9 mutations were suggested to
be early initiating events in MPN, and more recently
mutant CALR (mCALR) has been shown to mediate
thrombopoietin-independent activation of the thrombo-
poietin receptor MPL [9, 10]. mCALR is therefore an
ideal target for T cell-based immunotherapy given its ex-
pression profile and role in driving malignancy.
The genetic engineering of patient T cells with
tumour-specific TCRs, known as TCR gene therapy, is a
cellular immunotherapeutic approach which aims to
rapidly generate a pool of patient-specific tumour-reactive
T cells for adoptive transfer. The identification of
tumour-specific T cells and isolation of their TCRs repre-
sents a bottleneck in the development of TCR gene ther-
apy. However, the healthy donor-derived T cell pool
potentially represents a source that can be exploited for
the isolation of neoantigen-specific TCRs. In principle, T
cells expressing high affinity neoantigen-specific TCRs
should be identifiable in the naïve T cell repertoire.
In this study, we aimed to identify MHC class I neoepi-
topes derived from mCALR and isolate TCRs against such
neoepitopes with the potential to be utilized clinically for
TCR gene therapy. For the purpose of epitope discovery
we utilized a number of complimentary approaches.
Firstly, we used MHC peptide elution mass spectrometry
to try to identify potential mCALR neoepitopes. Secondly,
we used a MHC class I binding peptide prediction algo-
rithm to identify potential mCALR neoepitopes presented
by common European Caucasoid HLA class I alleles, gen-
erated pMHC multimers encoding these predicted CALR
peptides, and subsequently used combinatorial-encoded
mCALR multimer staining to screen mCALR+ MPN pa-
tients for CD8+ mCALR T cell responses. We extended
the MHC class I binding prediction analysis to include, in
addition to CALR, some other mutations found recur-
rently in hematological malignancies e.g. FBXW7, TP53,
andMYD88. These putative neoepitopes were used to gen-
erate a panel of pMHC multimers, to enable the isolation
of neoepitope-specific CD8+ T cells from the T cell pool of
readily available healthy human donor PBMC. Isolated pu-
tative neoepitope-specific T cells or TCRs were then ana-
lyzed for their ability to recognize cognate antigen in vitro.
Methods
Recurrent neoepitope peptide prediction
Putative mutated neoepitopes of 9, 10, or 11 amino acids
in length were determined using NetMHC 3.4 (http://
www.cbs.dtu.dk/services/NetMHC/). Neoepitopes were
chosen based on their predicted ability to bind common
European Caucasian HLA class I alleles (< 500 nM).
MHC peptide elution mass spectrometry
Two healthy donor-derived Epstein-Barr virus (EBV)-trans-
formed lymphoblastoid cell lines (LCLs), expressing a num-
ber of common HLA class I alleles (LCL 1 =HLA-A*01:01,
−A*03:01, -B*08:01, -B*35:01 and LCL 2 =HLA-A*02:01,
−A*11:01, -B*07:02, -B*44:02), were retrovirally transduced
with a pMX-mCALR-IRES-eGFP or pMX-eGFP alone vec-
tor. GFP+ LCLs were sorted to a high purity and expanded
to approximately 5 × 108 cells before being washed with
PBS and snap-frozen. Subsequent immunoprecipitation of
HLA class I molecules, elution of bound peptides, and ana-
lysis of peptides by liquid chromatography tandem mass
spectrometry (LC-MS/MS) was carried out as previously
described [11]. Briefly, cell pellets were ground using a
Retsch mixer mill (MM400) and then lysed in lysis buffer
(0.5% IGEPAL CA-630 [Sigma-Aldrich], 50 mM Tris-HCl
[pH 8.0], 150 mM NaCl, and protease inhibitors [complete
protease inhibitor cocktail; Roche Life Science]) for 1 h at
4 °C. Lysate was pre-cleared by passing over unconjugated
protein A sepharose [GE Healthcare] and then MHC:pep-
tide complexes were captured by protein A-coupled
pan-MHC class I-specific antibody W6/32. Dissociation of
heavy chain, beta-2 microglobulin and peptide was then
achieved using 10% acetic acid. Eluted MHC-peptides were
subsequently purified by fractionation using reversed
phased HPLC (RP-HPLC; Chromolith Speed Rod (Merck))
using an ÄKTAmicro HPLC system [GE Healthcare], as
described elsewhere [11].
Fractionated peptides were vacuum concentrated using
a Labconco Centrivac concentrator and resuspended to
a final volume of 20 μL in 0.1% formic acid in water
prior to LC-MS/MS analysis using an Eksigent NanoUl-
tra cHiPLC system [SCIEX] (microfluidic trap column
(200 μm× 0.5 mm ChromXP C18-CL [3 μm, 120 Å]) at
a flow rate of 5 μL/min; microfluidic analytical column
(75 μm× 15 cm ChromXP C18-CL [3 μm, 120 Å]) at a
flow rate of 300 nL/min across a gradient of increasing
concentration of acetonitrile in water supplemented with
0.1% formic acid) coupled to a TripleTOF® 5600+ mass
spectrometer [SCIEX). Each scan cycle consisted of MS1
spectra acquired for 200 msec and the top 20 precursor
ions fragmented using rolling collision energy and ac-
quired for 150 msec. Mass spectra were searched using
the Paragon™ algorithm of ProteinPilot™ v5 software
[SCIEX]. A custom database was assembled using the
combined Uniprot reference proteomes of Homo sapiens
(v2016_06), enhanced green fluorescent protein, and
mCALR sequences. Through the use of a decoy data-
base, data were subjected to a 5% false discovery rate
(FDR) cut-off.
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Neoepitope-specific T cell enrichment
Putative neoepitope HLA class I multimers were gener-
ated using conditional MHC class I ligands and peptide
exchange technology [12]. Healthy donor PBMCs isolated
from anonymised National Blood Service apheresis cones
were incubated with phycoerythrin (PE)-labelled neoepi-
tope multimers, before enrichment by magnetic-activated
cell sorting (MACS) using anti-PE microbeads [Miltenyi
Biotec]. Enriched cells were expanded using anti-CD3
mAb (30 ng/ml) [ebioscience] and IL-2 (3000 U/ml)
[Novartis]. Neoepitope multimer+ CD8+ T cell populations
were identified by combinatorial-encoded multimer stain-
ing [13]. To establish T cell clones, neoepitope multimer+
CD8+ cells were single-cell sorted and expanded using
anti-CD3 mAb (30 ng/ml) [ebioscience] and IL-2
(3000 U/ml) [Novartis]. T cell clones were confirmed by
neoepitope multimer and anti-CD8-APC (1:50) [BD]
staining.
Combinatorial-encoded multimer staining
For each putative mutated neoepitope being investigated,
HLA class I multimers were labelled with a unique com-
bination of two different streptavidin conjugated fluoro-
chromes, to enable the simultaneous detection of
two-colour combinations of multiple mutated neoepi-
tope multimers in a single sample [13]. The streptavidin
conjugates used were PE [BD], BB515 [BD], BV421
[BD], and BV650 [BD], allowing for 6 different
two-colour combinations. For staining, either 3 μl of
BV421 or PECy7, 2 μl of APC, BB515 OR BV650, or
1 μl of PE multimers per sample were taken into
low-protein binding microcentrifuge tubes [Thermo
Fisher Scientific] and centrifuged at 9600 x g for 2 min
at 4 °C. The supernatants were transferred to fresh
low-protein binding microcentrifuge tubes and adjusted
to a volume of 50 μl with 5% HS, PBS. PBMCs were
multimer stained as normal (Additional file 1), and also
stained with anti-CD8-APC (1:50) [BD] and live/dead
dye (1:200) [Life Technologies] for 30 min at 4 °C.
PBMCs were then washed twice in 5% HS, PBS and re-
suspended in 200 μl of buffer for acquisition using an
LSRII [BD] and analysis using FACSDiva software [BD].
MPN patient mCALR multimer staining
MPN patient peripheral blood samples were obtained
from the Queen Elizabeth Hospital Birmingham Clinical
Haematology department. PBMCs were isolated from
30-40mls of MPN patient blood by density centrifugation
over Ficoll-Paque [GE Healthcare]. Patient PBMCs were
analyzed for HLA-A*03:01 and HLA-B*07:02 expression
by PCR, as described in [14]. PBMCs from EBV+ healthy
donors were also isolated and used for positive control
EBV viral multimer staining. Putative mCALR peptides
were used to generate HLA-A*03:01 and HLA-B*07:02
multimers. Patient PBMCs were analyzed for mCALR T
cell responses by combinatorial-encoded multimer stain-
ing [13]. This study was conducted with ethical approval
by the South Birmingham Local Research Ethics Commit-
tee and in accordance with the Helsinki Declaration.
T cell reactivity assay
T cell reactivity was assessed by co-culturing T cells
overnight with relevant peptide-loaded targets cells or
cell lines, and detecting the T cell activation markers
IFN-γ and CD137. LCLs were incubated with relevant or
irrelevant peptides at a range of concentrations for
90 min at 37 °C, before being washed twice in excess
media. Target cells and T cells were incubated overnight
at a 1:1 ratio in triplicate cultures. Phorbol 12-myristate
13-acetate (PMA) (5 ng/ml) [Sigma-Aldrich] and iono-
mycin (500 ng/ml) [Sigma-Aldrich], or anti-CD3/CD28
human T cell activator dynabeads [Life Technologies],
were used as a positive control. T cells cultured alone
were used as a negative control. For intracellular IFN-γ
staining, golgi plug [BD] was added (1 μl/ml). T cells
were analyzed for IFN-γ and CD137 expression by flow
cytometry the following day (Additional file 1).
mCALR TCR retroviral plasmids
DNA was extracted from mCALR T cell clones using a
DNeasy blood and tissue kit [Qiagen]. mCALR TCRs
were sequenced using a high-throughput TCR gene cap-
ture technique [15]. Briefly, gDNA was sheared into
500 bp fragments and enriched for TCR genes by incu-
bating with an RNA-bait library encoding baits against
all TCR α and β variable gene loci. The enriched DNA
fragments were then sequenced by paired-end
(75–100 bp) Illumina sequencing. The output sequences
were then aligned to a reference genome in order to
identify TCR V(D)J genetic rearrangements and CDR3
sequences. The TCR α and β variable sequences were
codon optimised for expression in human cells and syn-
thesised and inserted into a retroviral pMP71 TCR flex
vector by Genscript [15].
Retroviral transduction
Healthy donor PBMCs or cell lines were transduced with
retroviral plasmids by spinfection. Briefly, Phoenix
Ampho cells were transfected with plasmid DNA and
pcl ampho DNA using Fugene 6 transfection reagent
[Promega]. Retrovirus was collected 48 h later, added to
retronectin-coated plates [Takara], and centrifuged at
2000 g, 32 °C for 2 h. Activated PBMCs or cell lines
were added to retrovirus-coated plates in appropriate
media, centrifuged at 500 g for 5 min and incubated at
37 °C, 5% CO2. mCALR TCR transduction efficiency was
determined by anti-mouse TCRβ-PE [1, 16] [Biolegend]
and/or relevant dual-colour multimer staining. Cell
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line transduction efficiency was determined by GFP
expression.
Results
MHC class I mCALR neoepitope discovery
Since recurrent CALR frameshift mutations result in the
expression of a novel 36 amino acid C-terminus, we in-
vestigated whether this mutant region of the protein
generates neoepitopes that are naturally processed and
presented by common European Caucasoid MHC class I
alleles. We used MHC class I peptide elution and mass
spectrometry to identify neoepitopes expressed on the
surface of LCLs retrovirally engineered with an eGFP
tagged mCALR minigene, encoding the novel 36 amino
acid sequence. These LCLs expressed a range of HLA
class I alleles, including HLA-A*01:01, −A*03:01,
−A*02:01, −A*11:01, -B*08:01, -B*35:01, -B*07:02 and
-B*44:02. Following MHC isolation, peptide elution, and
mass spectrometry analysis, we were able to identify sev-
eral peptides derived from wildtype CALR and eGFP,
however, no peptides derived from the 36 amino acid
mCALR C terminus were detected (Additional file 2).
Therefore, this data provides no evidence for the pro-
cessing and presentation of mCALR peptides in the con-
text of the HLA class I alleles studied.
Identification of mCALR CD8+ T cell responses in MPN
patients
After failing to detect any mCALR MHC class I neoepi-
topes by mass spectrometry, we utilized the MHC pep-
tide prediction algorithm NetMHC to identify putative
mCALR MHC class I neoepitopes. A number of mCALR
neoepitopes were predicted to bind strongly to
HLA-A*03:01 and HLA-B*07:02 (Table 1). We then uti-
lized MHC class I multimers containing these putative
mCALR neoepitopes for multiplexed screening of
mCALR T cell responses in the peripheral blood of
HLA-A*03:01+ and/or HLA-B*07:02+ mCALR+ MPN
patients (Additional file 3). While we could readily de-
tect virus-specific multimer+ CD8+ T cell populations in
PBMCs from 5 of the 7 MPN patients, putative mCALR
multimer+ CD8+ T cell populations were undetectable in
all patients, suggesting that these putative mCALR mul-
timer+ CD8+ T cell populations are not, or very weakly,
immunogenic (Fig. 1). It has been shown that T cell re-
sponses to naturally processed and presented antigens
may not always be detectable within cancer patients [17–
19]. Therefore, we began to explore if we could use a read-
ily available source of material – healthy human donor
material – to simultaneously identify mCALR neoepitopes
and isolate TCRs targeting these neoepitopes.
Isolation and functional testing of mCALR-specific TCRs
from healthy donor blood
We developed a protocol to isolate neoepitope-specific
TCRs from PBMC of healthy human donors using MHC
class I multimers (Additional file 4). We first demon-
strated that this protocol could be used to successfully
isolate very low frequency antigen-specific T cells by
isolating HLA-A*02:01-restricted cancer-testes (CT)
antigen-specific T cells from PBMC of HLA-A*02:01-ex-
pressing healthy human donors (Additional file 5). We
then produced HLA-A*03:01 and HLA-B*07:02
PE-conjugated multimers containing the predicted
mCALR neoepitopes to enrich for multimer-binding
CD8+ T cells in HLA-A*03:01+ and HLA-B*07:02+ healthy
donor PBMCs, respectively. A pool of putative neoepitope
multimers were first used to enrich multimer-bound T
cells from PBMC of healthy human donors (Fig. 2a).
Directly following isolation we were unable to clearly de-
tect enrichment of multimer-binding T cells in the small
sample of cells taken for analysis, presumably because of
the low precursor frequency of such T cells in the T cell
pool of healthy human donors. Conversely, when a larger
sample of cells were analyzed following expansion of
Table 1 Putative HLA class I mCALR neoepitopes
Neoepitope Peptide Predicted HLA
Restriction
Predicted HLA
binding affinity (nM)
RPRTSCREA CALR-REA HLA-B*07:02 12
SPARPRTSC CALR-SPA HLA-B*07:02 22
RMRRTRRKM CALR-RMR HLA-B*07:02 56
RPRTSCREAC CALR-REAC HLA-B*07:02 23
RMMRTKMRMR CALRp2 HLA-A*03:01 41
KMRMRRMRR CALRp7 HLA-A*03:01 35
RTRRKMRRK CALRp15 HLA-A*03:01 54
NetMHC was used to identify neoepitopes derived from the 36 amino acid
mCALR C terminus that are predicted to bind strongly (< 500 nM) to common
European Caucasoid HLA class I alleles
Fig. 1 Investigation of putative mCALR CD8+ T cell populations in
MPN. Combinatorial-encoded multimer staining was used to screen
mCALR+ MPN patients for putative mCALR multimer+ CD8+ T cell
populations in peripheral blood. Known cytomegalovirus (CMV)- and
Epstein–Barr virus (EBV)- specific multimers were included as positive
controls. Quantification of multimer+ CD8+ T cells within MPN patient
PBMCs is shown
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Tubb et al. Journal for ImmunoTherapy of Cancer  (2018) 6:70 Page 5 of 14
multimer-enriched T cells, numerous mCALR
multimer-binding CD8+ T cell populations could clearly
be detected using combinatorial-encoded multimer
staining (Fig. 2b). mCALR multimer+ CD8+ T cells were
subsequently cloned by single-cell sorting and ex-
panded using anti-CD3 antibodies and high dose IL-2
in a rapid expansion protocol. Utilizing this approach,
we successfully isolated twenty CALR-RMR and three
CALRp7 multimer+ CD8+ T cell clones which exhibited
> 99% dual-colour multimer staining (Fig. 2c).
We initially assessed the functionality of mCALR multi-
mer+ CD8+ T cell clones by assessing IFN-γ production
and CD137 up-regulation following co-culture with lym-
phoblastoid cell lines (LCLs) loaded with relevant mCALR
peptide (10 μM) or an irrelevant peptide (10 μM) (Fig. 3).
The majority of T cell clones showed specific reactivity to-
wards mCALR peptide (15/23), however a number of T cell
clones did not, suggesting that the binding of multimer
does not necessarily denote a functional T cell response, a
phenomenon observed previously [20]. However, we
successfully identified thirteen HLA-B*07:02-restricted
CALR-RMR and two HLA-A*03:01-restriced CALRp7 re-
active T cell clones. We proceeded to isolate the TCRαβ
variable gene sequences from the highest IFN-γ-producing
T cell clones (CALR-RMR clone 4, CALR-RMR clone 20,
CALRp7 clone 2 and CALRp7 clone 3) using TCR gene
capture technology (Additional file 6).
mCALR TCR-engineering of healthy donor T cells
TCR sequencing revealed that the same TCR clonotype
was identified in both of the sequenced CALR-RMR spe-
cific T cell clones (clone 4 and clone 20), which has been
denoted CALR-RMR TCR. Three different TCR clono-
types were identified in the two sequenced CALRp7 T
cell clones (clone 1 and clone 3), due to the expression
of two different TCRα chains in CALRp7 T cell clone 3,
denoted CALRp7 TCR 1, 2 and 3 (Additional file 6).
Following CALRp7 multimer staining, only CALRp7
TCRs 1 and 3 showed specific binding (data not shown),
therefore, only these CALRp7 TCRs were investigated
further. The three pairs of isolated TCR α and β genes
were each cloned into a pMP71 retroviral vector in a
TCRβ-P2A-TCRα configuration utilizing fully murine
TCR constant domains carrying an additional
disulfide-bridge. The expression cassette was
codon-optimized for expression in human cells. Healthy
donor T cells were engineered with our mCALR TCRs
using retroviral transduction. mCALR TCR surface ex-
pression was confirmed by mouse TCRβ staining and
specific mCALR multimer staining (Fig. 4a). Transduc-
tion efficiencies ranged from 58.9–38.3% using mouse
TCRβ staining, and 46.6–8.74% using multimer staining.
Of note, the percentage of multimer+ CD8+ T cells was
significantly lower than the percentage of mouse TCRβ+
CD8+ T cells for CALR-RMR TCR, suggesting the
CALR-RMR TCR may have a particularly low affinity for
CALR-RMR multimer binding. We assessed the antigen
sensitivity of T cells engineered with mCALR TCRs by
co-culture with LCLs loaded with decreasing concentra-
tions of mCALR peptide and measured IFN-γ produc-
tion by intracellular staining (Fig. 4b). CALRp7 TCR 3
showed no reactivity against CALRp7 peptide at any
concentration tested. In contrast, CALR-RMR and
CALRp7 TCR 1 displayed peptide reactivity with EC50
values of 5487 nM and 975 nM, respectively. However, it
should be noted that these EC50 values may be underes-
timated, as it is not clear if these T cell responses are
maximal at 104nM. These data suggest that both of these
TCRs display a low affinity for their respective p:MHC
complexes. To determine if the mCALR TCRs were able
to recognize processed and presented mCALR antigen,
we engineered HLA-A*03:01+ HLA-B*07:02+ LCLs with
(See figure on previous page.)
Fig. 2 mCALR multimer+ CD8+ T cell isolation (a) Pools of HLA-A*03:01 and HLA-B*07:02 multimers containing putative mCALR neoepitopes were
used to enrich CD8+ T cells from HLA-A*03:01+ and HLA-B*07:02+ healthy donor PBMCs. (n = 3) (b) Following enrichment and expansion of mCALR
multimer+ T cells, numerous mCALR multimer+ CD8+ T cell populations were detected by combinatorial-encoded multimer staining. cmCALR multimer+
CD8+ T cell clones were isolated by single-cell sorting and identified by single or dual-colour multimer staining
Fig. 3 mCALR T cell clone peptide reactivity mCALR multimer+
CD8+ T cell clones were co-cultured with LCLs loaded with 10 μM of
mCALR peptide or irrelevant peptide and assessed for reactivity by
analysing CD137 expression by flow cytometry. CALR-RMR T cell
clones were incubated with anti-CD3/CD28 beads as a positive
control. (n = 1)
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an eGFP tagged mCALR minigene, which was confirmed
by RT-PCR (Additional file 7). Additionally, we engineered
MARIMO cells, an essential thrombocythaemia cell line
known to express a type 1 CALR frameshift mutation
(c.1099_1159del; L367 fs*43), with HLA-A*03:01- and
HLA-B*07:02-expressing retroviral vectors (Additional file
7). However, mCALR TCR-engineered T cells were unable
to recognize mCALR-expressing target cells (Fig. 4c). The
lack of recognition of the mCALR expressing cell lines by
the TCR engineered T cells could have been due to their
low affinity for mCALR peptide:MHC, or alternatively
may be due to a lack of processing and presentation of
these putative mCALR peptides in the context of
HLA-A*03:01 and HLA-B*07:02.
Isolation of putative neoepitope TCRs targeting recurrent
mutations in hematological malignancies
We next turned our attention to other mutations found
recurrently in hematological malignancies. We firstly
identified somatic mutations found recurrently in
hematological malignancies using the catalogue of somatic
mutations in cancer (COSMIC). As before, we utilized the
MHC peptide prediction algorithm NetMHC to identify
putative neoepitopes encoding these mutations that were
predicted to bind strongly to common European Caucas-
oid HLA class I alleles. We found a number of neoepi-
topes predicted to bind to HLA-A*11:01 and
HLA-B*07:02 (Table 2). These included neoepitopes de-
rived from hot-spot mutations in the tumour suppressor
(See figure on previous page.)
Fig. 4 mCALR TCR-engineered T cell recognition of mCALR-expressing target cells (a) mCALR TCR transduction efficiency was determined by
mouse TCRβ (mTCRβ) staining and dual-colour mCALR multimer staining. Mock-transduced T cells were used to determine positive staining. (n =
3) (b) mCALR TCR-engineered T cells were co-cultured with LCLs loaded with decreasing concentrations of mCALR peptide at a 1:1 ratio and
assessed for reactivity by IFN-γ intracellular cytokine staining. (n = 3) (c) mCALR TCR-transduced T cells were co-cultured with mCALR-expressing
target cells at a 1:1 ratio and assessed for reactivity by IFN-γ intracellular cytokine staining. (n = 3)
Table 2 Putative neoepitopes encoding mutations found recurrently in hematological cancers
Protein Mutation Putative epitope Peptide HLA-Restriction Predicted HLA
binding affinity (nM)
Hematopoietic and Lymphoid
Cancer Frequencies
CALR K385Nfs*47 RPRTSCREA CALR-REA HLA-B*07:02 12 Essential thrombocythemia (31.1%),
Myelofibrosis (27.3%)
SPARPRTSC CALR-SPA HLA-B*07:02 22
RMRRTRRKM CALR-RMR HLA-B*07:02 56
RPRTSCREAC CALR-REAC HLA-B*07:02 23
RMMRTKMRMR CALRp2 HLA-A*03:01 41
KMRMRRMRR CALRp7 HLA-A*03:01 35
RTRRKMRRK CALRp15 HLA-A*03:01 54
FBXW7 R465C TVCCMHLHEK TVC HLA-A*11:01 29 T-ALL (15.4%), Precursor T cell lymphoblastic
lymphoma (15.6%)
STVCCMHLHEK STV HLA-A*11:01 65
HTSTVCCMHLH HTS HLA-A*11:01 495
R465H STVHCMHLH STVH HLA-A*11:01 78
TVHCMHLHEK TVH HLA-A*11:01 43
P53 R248Q SSCMGGMNQR NQR HLA-A*11:01 177 Mantle cell lymphoma (9.1%), B-ALL (6.9%),
T-ALL (8.6%), Follicular lymphoma (18.5%),
AML (7%), MDS (7.3%), CLL (10.9%), T cell l
ymphoma (18.6%), Burkitt’s lymphoma (18%),
Diffuse large B cell lymphoma (12.6%)
R248W SSCMGGMNWR NWR HLA-A*11:01 320
MyD88 L265P RPIPIKYKAM RPI HLA-B*07:02 20 MGUS (46.8%), Waldenström’s macroglobulinaemia
(86.3%), Diffuse large B cell lymphoma (14.4%)
SPGAHQKRPI SPG HLA-B*07:02 40
IDH2 R140Q SPNGTIQNIL SPN HLA-B*07:02 72 AML (9.7%), Angioimmunoblastic T cell
lymphoma (24.1%)
DNMT3A R882H VSNMSHLAR VSN HLA-A*11:01 61 AML (20.4%), MDS (9.1%), T cell lymphoma (25.7%),
STAT3 Y640F QIQSVEPFTK QIQ HLA-A*11:01 60 T cell large granular lymphocytic leukaemia
(34.3%), Adult T-cell leukemia/lymphoma (21.1%)
The catalogue of somatic mutations in cancer (COSMIC) was used to identify mutations found recurrently in hematological cancers. The MHC binding algorithm
NetMHC3.4 was utilized to identify putative neoepitopes encoding these mutations that were predicted to bind strongly to common European Caucasoid HLA
class I alleles. T-ALL T cell acute lymphoblastic leukemia, B-ALL B cell acute lymphoblastic leukemia, AML acute myeloid leukemia, MDS myelodysplastic syndrome,
CLL chronic lymphocytic leukemia, MGUS monoclonal gammopathy of undetermined significance
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genes FBXW7 and TP53, and also point mutations in
MYD88, IDH2, DNMT3A and STAT3. We then generated
multimers containing these neoepitopes to enrich for
neoepitope-specific T cells from healthy donor PBMC.
Following enrichment and expansion, we detected
FBXW7 TVH, FBXW7 TVC, TP53 NQR and MYD88 RPI
multimer+ CD8+ T cell populations using combinatorial-
encoded multimer staining (Fig. 5a). The cloning of these
multimer+ CD8+ T cell populations resulted in the isola-
tion of four FBXW7 TVH-, four FBXW7 TVC-, and five
p53 NQR-specific CD8+ T cell clones, which exhibited
bright dual-colour multimer staining (Fig. 5b). We then
assessed the reactivity of these T cell clones against
peptide-loaded LCLs using IFN-γ intracellular cytokine
staining, and found that only one T cell clone displayed
specific peptide reactivity, namely FBXW7 TVH clone 2,
as determined by CD137 upregulation upon stimulation
(Fig. 5c).
Functional testing of mutant FBXW7-specific TCRs from
healthy donor blood
Encouraged by the response of TVH clone 2 against the
mutated peptide, we next determined whether FBXW7
TVH clone 2 was able to discriminate between the mu-
tant FBXW7 (mFBXW7) TVH peptide and the wildtype
FBXW7 peptide, in which the histidine residue at P3
was reverted back to the wildtype arginine residue. For
this purpose, T cells were co-cultured with LCLs loaded
with decreasing concentrations of either the mutated or
wildtype FBXW7 peptide and IFN-γ production was
assessed by intracellular cytokine staining. FBXW7 TVH
clone 2 showed no recognition of LCLs loaded with any
concentration of wildtype peptide, however, it displayed
specific recognition of LCLs loaded with mFBXW7 TVH
peptide (EC50 value 648 nM) (Fig. 6a). These results
demonstrate that the TCR expressed by this T cell clone
can discriminate between the mutant and WT peptides,
displaying fine peptide specificity towards the mFBXW7
peptide with a single amino acid substitution.
We then sought to determine if the putative
mFBXW7 TVH neoepitope recognized by FBXW7
TVH clone 2 could be processed and presented in the
context of HLA-A*11:01. For this purpose we engi-
neered HLA-A*11:01+ LCLs with an eGFP tagged
mFBXW7 minigene encoding the c.1394 G > A
p.R465H mutation flanked by 15 wildtype nucleotides
(mFBXW7+ LCL), and confirmed mFBXW7 expression
by RT-PCR (Additional file 8). Encouragingly, following
co-culture, FBXW7 TVH clone 2 showed reactivity to-
wards mFBXW7+ LCLs, but showed no reactivity to-
wards non-engineered LCL expressing only wildtype
FBXW7 (Fig. 6b). These findings suggest that the
FBXW7 TVH neoepitope encoding the R465H muta-
tion is capable of being processed and presented on the
surface of target cells by HLA-A*11:01, for recognition
by FBXW7 clone 2 T cells.
Finally, we assessed whether FBXW7 TVH clone 2 can
recognize tumour cells naturally expressing endogenous
levels of FBXW7 R465H mutated protein. Therefore, we
engineered two T cell acute lymphoblastic leukaemia
(T-ALL) cell lines (CML-T1 and RPMI8402), with
confirmed FBXW7 c.1394 G >A p.R465H mutant protein
expression, with an HLA-A*11:01 retroviral vector
(Additional file 8). Prior to T cell-tumor cell co-culture,
some tumor cells were pre-treated with 200 IU/ml
rh-IFN-γ for 24 h, as this was shown to induce upregula-
tion of MHC (data not shown), indicative of upregulation
of the immunoproteasome. Following co-culture, FBXW7
TVH clone 2 did not show reactivity towards T-ALL cell
lines, whether untreated or pre-treated with IFN-γ (Fig. 6c).
The lack of recognition of T-ALL cell lines may poten-
tially be due to defects in antigen processing and presen-
tation. As FBXW7 provides substrate recognition to a
multi-subunit ubiquitin ligase complex that is respon-
sible for ubiquitin-dependent degradation of proteins,
mutations in FBXW7 may adversely affect proteasomal
processing and presentation of antigens, including
FBXW7 itself. Therefore, to determine whether CML-T1
and RPMI8402 cells have any global antigen presenting
defects, we infected cells with an EBNA3B modified vac-
cinia ankara (MVA) virus encoding the EBV nuclear
antigen 3B (EBNA3B), which contains the IVT epitope
(EBNA3B416–424) restricted through HLA-A*11:01
[21]. The infected cells were then co-cultured with an
EBNA3B IVT-reactive T cell clone (Fig. 6d). We found
that IVT-reactive T cells were able to recognize CML-T1
EBNA3B MVA infected cells, but not RPMI8402
EBNA3B MVA infected cells, suggesting that RPMI8402
cells, but not CML-T1 cells, are defective in processing
antigen. Therefore, this may explain the lack of recogni-
tion of RPMI8402 cells by FBXW7 TVH clone 2, but
does not explain their lack of recognition of CML-T1.
Furthermore, the lack of recognition of the CML-T1 and
RPMI8402 may be due to a relatively low affinity for
FBXW7 TVH peptide, thereby preventing it from recog-
nizing physiological levels of the FBXW7 TVH pre-
sented on tumor cells.
Discussion
The purpose of this study was to simultaneously identify
neoepitopes containing somatic cancer mutations found
recurrently in hematological malignancies, and TCRs re-
active against such neoepitopes from the healthy human
donor T cell pool. mCALR was initially chosen as an at-
tractive target for immunotherapy, given its expression
of a novel stretch of 36 amino acids, and its high fre-
quency in JAK2wt MPN patients (~ 80%) [7, 8]. How-
ever, our results failed to detect any mCALR
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Fig. 5 (See legend on next page.)
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neoepitopes presented by common European Caucasoid
HLA class I alleles using MHC peptide elution mass
spectrometry. Additionally, using MHC class I multimer
staining against predicted mCALR epitopes, mCALR
CD8+ T cells were undetectable in the small number of
mCALR+ MPN patient PBMC we screened. Interest-
ingly, CD8+ T cells with reactivity against putative
mCALR neoepitopes could be repeatedly enriched from
the healthy human donor T cell pool. There is currently
no evidence to suggest that mCALR induces tolerance in
mCALR+ patients, and of interest, our mCALR-derived
neoepitopes are not shared with any self-peptides. It is
most likely however, that following mCALR multimer
enrichment and multiple rounds of stimulation, we
enriched mCALR-specific T cells from healthy donor
blood, where they were presumed to be of a naïve T cell
precursor frequency. On the other hand, we performed
mCALR multimer staining of mCALR+ patient PBMC
directly ex vivo, without prior enrichment and expan-
sion, where antigen-specific T cells of naïve frequency
would be under the detection limit of multimers.
Although putative mCALR-specific TCRs showed re-
activity towards cognate peptide, they were unable to
recognize naturally processed and presented mCALR+ tar-
get cells. Taken together, we found no evidence that the
predicted mCALR peptides studied are naturally proc-
essed and presented in the context of the HLA class I al-
leles investigated. However, since the mCALR C-terminus
contains many hydrophilic residues, which are particularly
difficult to bind and separate using C18 reverse-phase
HPLC, a false-negative result is possible, and is a caveat of
using this type of approach for epitope discovery.
Although this study focused on CD8+ T cells, CD4+ T
cells, which are classically described as helper T cells,
can also exhibit direct anti-tumour cytotoxic function in
both mice and humans [22, 23]. Numerous studies have
(See figure on previous page.)
Fig. 5 Isolation of additional putative neoepitope TCRs targeting recurrent mutations in hematological malignancies (a) Neoepitope-specific CD8+
T cells were enriched using neoepitope-bound multimers. After expansion of enriched cells, neoepitope multimer+ CD8+ T cell populations could
be detected by combinatorial-encoded multimer staining. (n = 1) (b) Neoepitope multimer+ CD8+ T cells were cloned by single-cell sorting. Four
FBXW7 TVH, four FBXW7 TVC and five p53 NQR CD8+ T cell clones were isolated. Representative multimer staining flow plots are shown with dual-
colour multimer staining shown on the x and y axis. c Neoepitope T cell clones were assessed for reactivity against neoepitope peptide- or irrelevant
peptide- loaded LCLs (10 μM) by CD137 staining. (n = 1)
Fig. 6 Mutant FBXW7 TVH clone 2 recognizes naturally processed and presented mFBXW7 antigen (a) FBXW7 TVH clone 2 was co-cultured with
LCLs loaded with decreasing concentrations of FBXW7 mutant or wildtype peptide at a 1:1 ratio. Reactivity was determined by IFN-γ intracellular
cytokine staining. (n = 3) (b) FBXW7 TVH clone 2 was co-cultured with mFBXW7+ LCL or mock-transduced LCL at a 1:1 ratio. Reactivity was determined
by IFN-γ intracellular cytokine staining. (n = 3) (c) FBXW7 TVH clone 2 was co-cultured with HLA-A*11:01+ CML-T1 or HLA-A*11:01+ RPMI8402, with or
without IFN-γ pre-treatment, at a 1:1 ratio. Reactivity was determined by IFN-γ intracellular cytokine staining. (n = 2) (d) HLA-A*11:01+ CML-T1, HLA-
A*11:01+ RPMI8402 or HLA-A*11:01+ LCLs were infected with an EBNA3B MVA encoding the EBV derived epitope IVT, or an empty control MVA. IVT-
specific CD8+ T cells were co-cultured with EBNA3B MVA infected target cells at a 1:1 ratio. Reactivity was determined by IFN-γ intracellular cytokine
staining. (n = 2)
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highlighted the contribution of tumour-reactive CD4+ T
cells to cancer immunotherapy efficacy [1, 24, 25]. Inter-
estingly, CD4+ T cell responses against long mCALR
peptides that contain our minimal mCALR epitopes of
interest (CALR-RMR and CALRp7) have recently been
discovered in the blood of mCALR+ MPN patients [16].
However, when Holmström et al. performed mCALR
minimal epitope screening of T cells reactive to long
mCALR peptides by IFN-γ ELIspot, CALR-RMR and
CALRp7 peptides were not included. In addition, an
HLA-DR-restricted TCR was isolated which was able to
recognize autologous mCALR+ hematopoietic stem cells
and mCALR+ monocytes, suggesting that mCALR can
give rise to specific TCRs with therapeutic potential for
treating mCALR+ MPN patients [16, 26]. However, in
agreement with our findings, the study by Holmström et
al. was also unable to isolate CD8+ mCALR-reactive T
cell clones. These findings suggest that mCALR is a
promising target for CD4+ T cell based immunotherapy.
However, whether mCALR is targeted by CD8+ T cells
warrants further investigation. It is also important to
note that CALR plays a key role in the MHC class I pro-
cessing pathway, and thus mutations in CALR may
interfere with this process. Hence, detection of MHC
class II-restricted responses to mCALR, may be more
likely than MHC class I responses.
After turning our attention to other mutations found re-
currently in hematological malignancies, we successfully
identified a CD8+ T cell clone with reactivity against the
R465H hot-spot mutation in FBXW7. FBXW7 is among
one of the most frequently mutated cancer genes, with a
cancer-wide average frequency of 6%, and a frequency of
15–31% in T-ALL [27]. FBXW7 is an F-box protein family
member that provides substrate recognition to the SCF
ubiquitin ligase complex. The SCF ubiquitin ligase com-
plex is responsible for the ubiquitination of proteins des-
tined for proteasomal degradation, and is therefore
important in many cellular processes, including cellular
division and cell cycle progression. FBXW7 has been iden-
tified as a tumour-suppressor gene following studies
showing its role in the ubiquitin-dependent degradation
of a number of oncoproteins [28]. It is therefore unsur-
prising that loss-of-function mutations within FBXW7 are
found recurrently in a diverse range of cancers. CD8+
mFBXW7-specific T cells showed specific recognition of
mutant peptide and engineered target cells, suggesting
that the mFBXW7 peptide is naturally processed and pre-
sented, and suggesting the discovery of a novel neoepi-
tope. However, the particular T cell clone isolated was
unable to recognize mFBXW7+ T-ALL cell lines, possibly
owing to the relatively low affinity of its TCR for
mFBXW7 peptide:MHC complex. Another possibility is
that mutations in FBXW7 may affect the proteasomal pro-
cessing of the FBXW7 protein itself, preventing FBXW7
antigen processing and presentation. We attempted to ad-
dress this possibility (Fig. 6d), where we found that
CML-T1 cells, but not RPMI8402 cells, were able to
present the EBV antigen EBNA3B and activate
EBNA3B-specific T cells. Interestingly, CML-T1 cells were
found to be heterozygous for the FBXW7 R465H muta-
tion, whereas RPMI8402 cells are homozygous (data not
shown). This finding may suggest that FBXW7 R465H
causes deficiency in antigen processing and presentation,
but that a single copy of wildtype FBXW7 is able to rescue
this phenotype in CML-T1 cells. Further work is therefore
needed to conclude whether FBXW7 R465H causes global
antigen processing and presentation defects, and thus de-
termine if mFBXW7 is a suitable target antigen for
immunotherapy.
Throughout this study we utilized conditional MHC
class I ligands and peptide exchange technology to
allow the flexible and high-throughput generation of
neoepitope-bound MHC class I multimers for enrich-
ment of neoepitope-specific CD8+ T cells [12]. Using
this method, we isolated numerous multimer+ CD8+ T
cell clones, however, a significant number of these
showed no reactivity against relevant peptide-loaded
LCLs, demonstrating that multimer binding does not
always indicate functional reactivity. However, it should
be noted that the sole use of CD137 and IFN-γ for
assessing T cell reactivity might have underestimated
the number of neoepitope-reactive CD8+ T cell clones
expressing alternative cytokines and/or activation
markers. Although multimers are powerful tools for
isolating antigen-specific T cells, we encountered two
limitations in their use: 1. the isolation of low-affinity
antigen-specific T cells, and 2. the peptide complexes in
question may not be naturally processed in target cells.
Therefore, whilst this approach successfully identified a
novel neoepitope (mFBXW7 TVH), it is not well suited
to simultaneous epitope and high-affinity TCR discov-
ery, since the identification of high affinity TCRs is im-
portant for therapeutic efficacy.
An alternative approach would involve the induction
of neoepitope-specific T cell responses using
antigen-specific stimulation e.g. autologous antigen
presenting cells transfected with neoepitope minigenes.
An induction approach would select those TCRs with
reactivity against neoantigens that have been naturally
processed and presented, therefore likely reducing the
number of low-affinity non-functional TCRs isolated,
and increasing TCR discovery efficiency. This type of
approach has been successfully used by others to iso-
late neoantigen-reactive T cells from the naïve T cell
repertoires of healthy blood donors [17], therefore
using this approach may uncover many more high af-
finity recurrent neoepitope-reactive TCRs with greater
therapeutic potential.
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Conclusions
We investigated whether mutations found recurrently in
hematological malignancies encode immunogenic neoan-
tigens presented by common European Caucasoid HLA
class I alleles. While mCALR did not appear to be im-
munogenic in the context of the HLA class I alleles inves-
tigated, we isolated an mFBXW7-specific TCR with
reactivity against mFBXW7-engineered target cells, sug-
gesting the identification of a novel neoepitope expressed
recurrently in a diverse range of cancers, including
T-ALL.
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